Methylphenidate-induced motor activity in rats: modulation by melatonin and vasopressin

Edgar Appenrodt1, Helmut Schwarzberg

  • 1Institute of Neurophysiology, Otto-von-Guericke University, Leipziger Strasse 44, 39120 Magdeburg, Germany. edgar.appenrodt@medizin.uni-magdeburg.de

Insights

Methylphenidate (MPH) increases motor activity, influenced by the pineal gland and vasopressin (AVP). Melatonin and AVP receptor blockade alter MPH

Area of Science:

  • Neuroscience
  • Endocrinology
  • Behavioral Pharmacology

Background:

  • Methylphenidate (MPH) enhances motor activity, modulated by the light-dark cycle.
  • MPH affects the hypothalamo-neurohypophysial axis, including vasopressin (AVP).
  • The pineal gland and its hormone melatonin (Mel) influence AVP's behavioral effects.

Purpose of the Study:

  • To investigate the involvement of the pineal gland, melatonin (Mel), and vasopressin (AVP) in MPH-evoked motor activity stimulation.

Main Methods:

  • Comparison of motor activity in pinealectomized (PE) and sham-operated (SO) rats after MPH administration.
  • Assessment of Melatonin (Mel) effects on MPH-induced activity in PE and SO rats.
  • Evaluation of the V1a receptor antagonist (AAVP) effects on MPH-induced activity in PE and SO rats.

Main Results:

  • Pinealectomy significantly increased MPH-induced motor activity compared to sham-operated rats.
  • Melatonin pretreatment diminished MPH effects in PE rats and augmented them in SO rats, normalizing responses when compared.
  • AVP receptor blockade (AAVP) augmented MPH activity in SO rats and abolished differences between SO and PE rats.

Conclusions:

  • The pineal gland, via melatonin, and the neuropeptide vasopressin (AVP) modulate the behavioral stimulation induced by Methylphenidate (MPH).

Related Concept Videos

Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...